Does medicinal cannabis have strong growth potential?

Team Veye | 30-Nov-2020 strong growth potential

As the cannabis sector evolves, the importance of building an industry and innovation is unfolding. 

While the past year has seen some volatility in supply and demand on a global basis, there continues to be strong evidence of growing awareness, support and demand for safe, high quality medicinal cannabis treatments both in Australia and in the expanding number of legal overseas markets.

The number of prescribing medical professionals and patients continues to rise, and the body of medical evidence supporting the use of medicinal cannabis across a variety of indications continues to strengthen.

As with most developing industries, it is expected to see some rationalisation and consolidation in the medicinal cannabis sector as markets continue to develop.

In November 2019, Drug Research Body Drug Science had caused widespread anticipation as it announced the intent to create the largest medical cannabis registry in Europe. By June 2020, medical cannabis suppliers had been identified and testing of patient pathways ad begun.

Project Twenty21 is a patient registry providing access to medical cannabis while simultaneously gathering data on treatment efficacy. It has currently enrolled more than 8,000 patients through clinics and independent prescribers

Drug Science hopes that the findings of Project Twenty21 will provide evidence for NHS funding where the benefits of treatment with medicinal cannabis are proven to outweigh the potential risks in a number of key areas including Anxiety Disorder, Chronic Pain, Multiple Sclerosis (MS) and Tourette’s Syndrome besides many other diseases.

Australia’s cannabis economy is growing exponentially following the country’s 2016 move to permit the medical use of cannabis. Industry analysts are projecting further legislative shifts in favour of cannabis and hemp once the worst impacts of the pandemic have subsided.


Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website, and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

veye logo

Grab Your Free Report On 5 ASX Dividend Stocks To Buy In 2024